Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting

Sponsor
Tanta University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05640453
Collaborator
(none)
70
1
2
5
14.1

Study Details

Study Description

Brief Summary

The aim of this study is to determine the effect of pregabalin versus dexmedetomidine on the treatment and lasting duration of delirium in fast tracking elderly patients after Coronary Artery Bypass Grafting.

Detailed Description

Delirium is an acute brain disorder that involves changes in consciousness, attention, cognition, and perception.The incidence of postoperative delirium (POD) is high among patients undergoing cardiac surgery, ranging from 20 to 50%, and the risk is even higher in the elderly.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Pregabalin Versus Dexmedetomidine for Delirium Treatment After Coronary Artery Bypass Grafting: A Randomized Double-Blind Trial
Anticipated Study Start Date :
Dec 15, 2022
Anticipated Primary Completion Date :
May 15, 2023
Anticipated Study Completion Date :
May 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Pregabalin group

Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.

Drug: Pregabalin
Patients will receive pregabalin capsules (75 mg) every 12 h for 24 hours by nasogastric tube.

Active Comparator: Dexmedetomidine group

Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min) followed by an infusion of 0.2 to 0.7 μg/h.

Drug: Dexmedetomidine
Patients will receive a bolus dose of 0.4 μg/kg dexmedetomidine (over a period of 10 to 20 min)

Outcome Measures

Primary Outcome Measures

  1. Percent of delirium treatment [24 hour postoperatively]

    Assessment of delirium will be performed preoperatively and postoperatively at 12-h intervals or as needed according to the patient's condition using the confusion assessment method (CAM)

Secondary Outcome Measures

  1. Level of sedation [24 hour postoperatively]

    Sedation level will be assessed by using the Ramsey sedation scale.

  2. Incidence of weaning from mechanical ventilation [1 week postoperatively]

    percent of patients who weaned from mechanical ventilation

  3. Length of hospital stay [1 month postoperatively]

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • CABG patients ≥ 65 years of age both genders American Society of Anesthesiologists (ASA) physical status classification II or III planned for fast track developed postoperative delirium (POD).
Exclusion Criteria:
  • Patients who had history of psychiatric diseases; inability to communicate;

  • previous history of POD; preoperative sick sinus syndrome, allergy/sensitivity to pregabalin or dexmedetomidine, severe bradycardia (heart rate <50 beat per minute), second-degree or above atrioventricular block without pacemaker; severe hepatic or renal insufficiency.

  • Previous cardiac or thoracic surgery, known diagnosis of depression or other major psychiatric diseases, cognitive impairment or inability to cooperate with the study, renal insufficiency, and history of substance abuse.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Islam Morsy Tanta El-Gharbia Governorate Egypt

Sponsors and Collaborators

  • Tanta University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Islam Morsy, Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Tanta University
ClinicalTrials.gov Identifier:
NCT05640453
Other Study ID Numbers:
  • 35912/10/22
First Posted:
Dec 7, 2022
Last Update Posted:
Dec 7, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 7, 2022